

OFFICIAL RECORD

MATERIALS LICENSE

Amendment No. 19

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below, to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

DL-090696-02

<p>Licensee</p> <p>1. Carilion Radford Community Hospital</p> <p>2. 700 Randolph Street Radford, Virginia 24141-2430</p>	<p>In accordance with letter dated May 13, 1996</p> <p>3. License Number 45-07950-01</p> <p>is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration Date July 31, 2004 (Extended)</p> <hr/> <p>5. Docket or Reference No. 030-03326</p>
--	--

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Iodine 131	C. Sodium iodide (in capsule form only)	C. 1.1 gigabecquerels (300 millicuries)

9. Authorized Use:
- A. Medical use described in 10 CFR 35.100.
 - B. Medical use described in 10 CFR 35.200, except studies involving radioactive gases.
 - C. Treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma, in single patient doses.

CONDITIONS

- 10. Location for use: **Carilion Radford Community Hospital, 700 Randolph Street, Radford, Virginia.**
- 11. Radiation Safety Officer: **Bharat R. Patel, M.D. and in his absence Ivan Roger Morehouse, M.D.**

9609260139 960906
PDR ADOCK 03003326
C PDR

MJK 20/11

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number 45-07950-01

Docket or Reference Number 45-03326

Amendment No. 19

CONDITIONS

Continued -

12. Authorized users:

- A. Bharat R. Patel, M.D. Medical uses identified in 10 CFR 35.100, 35.200, iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.
- B. Ivan Roger Morehouse, M.D. Medical uses identified in 10 CFR 35.100, 35.200, iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.
- C. Donna Aubrey, M.D. Medical uses identified in 10 CFR 35.100, 35.200, iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

13. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

14. The licensee shall maintain records of information important to safe and effective decommissioning at the licensee's facilities listed in Condition 10 per the provision of 10 CFR 30.35(g) until this license is terminated by the Commission.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations

- A. Application dated December 20, 1993
- B. Letter dated July 22, 1994 [Radiopharmaceutical therapy and other additional information]
- C. NRC letter dated March 1, 1996 [Extends expiration date pursuant to 10 CFR 30.36.]
- D. Letter dated May 13, 1996 (name change)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

DATE SEP 05 1996

BY Earl G. Wright

Region II, Division of Nuclear Materials Safety
101 Marietta Street, N.W., Suite 2900
Atlanta, GA 30323-0199

N:\MLICENSE\45-07950\A19

9/1/96

